

CITATION REPORT

List of articles citing

Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events

DOI: 10.1111/j.1743-6109.2004.04024.x
Journal of Sexual Medicine, 2004, 1, 161-7.

Source: <https://exaly.com/paper-pdf/36831200/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
42	Phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>BJU International</i> , 2005 , 96, 257-80	5.6	153
41	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 459-68	3.8	19
40	Erectile dysfunction in patients with coronary artery disease. <i>International Journal of Impotence Research</i> , 2005 , 17, 209-15	2.3	19
39	3β5βcyclic nucleotide phosphodiesterase 11A: localization in human tissues. <i>International Journal of Impotence Research</i> , 2005 , 17, 320-5	2.3	58
38	Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 32M-36M	3	17
37	The therapeutic dilemma: how to use tadalafil. <i>Journal of Developmental and Physical Disabilities</i> , 2005 , 28 Suppl 2, 74-80		36
36	Tadalafil: a clinical update. <i>Aging Health</i> , 2005 , 1, 203-214		3
35	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 531-40	4.1	18
34	Frequently asked questions about tadalafil for treating men with erectile dysfunction. <i>The Journal of Mens Health & Gender: the Official Journal of the International Society for Mens Health & Gender</i> , 2005 , 2, 141-157		1
33	Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1026-7	2.9	0
32	The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. <i>Journal of Sexual Medicine</i> , 2006 , 3, 28-36; discussion 36	1.1	230
31	Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. <i>Journal of Sexual Medicine</i> , 2006 , 3, 716-722	1.1	33
30	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , 2006 , 50, 351-9	10.2	139
29	Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. <i>American Journal of Cardiology</i> , 2006 , 97, 1778-84	3	63
28	The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. <i>International Journal of Impotence Research</i> , 2007 , 19, 55-61	2.3	57
27	An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease. <i>BJU International</i> , 2007 , 99, 387-93	5.6	13
26	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1547-54	2.9	20

25	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	10.2	73
24	Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. <i>Journal of Sexual Medicine</i> , 2007 , 4, 166-175	1.1	36
23	Looking to the future for erectile dysfunction therapies. <i>Drugs</i> , 2008 , 68, 231-50	12.1	55
22	The cardiovascular safety of tadalafil. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 43-52	4.1	8
21	Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S420-2	14.6	7
20	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		7
19	[Erectile dysfunction in the cardiovascular patient]. <i>Medicina Clínica</i> , 2009 , 132, 309-10	1	
18	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
17	Cardiovascular aspects of sexual medicine. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1608-26	1.1	80
16	Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. <i>International Journal of Clinical Practice</i> , 2010 , 64, 848-57	2.9	158
15	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 347-65	3.2	12
14	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
13	A case of acute pulmonary thromboembolism after taking tadalafil. <i>Tuberculosis and Respiratory Diseases</i> , 2012 , 73, 231-3	3.2	1
12	Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. <i>PLoS ONE</i> , 2014 , 9, e91327	3.7	27
11	Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. <i>European Journal of Pharmacology</i> , 2015 , 765, 574-81	5.3	10
10	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 439-49	4	12
9	Etiologies and Mechanisms of Ischemic Stroke Associated with Sexual Intercourse: A Literature Review. <i>Cerebrovascular Diseases</i> , 2021 , 1-9	3.2	
8	NHG-Standaard Erectiele disfunctie. 2009 , 1291-1313		

- 7 Erectile Dysfunction. **2009**, 519-526
- 6 NHG-Standaard Erectiele disfunctie. **2011**, 1495-1517
- 5 PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. **2015**, 185-193
- 4 Erectile Dysfunction and Penile Rehabilitation After Robot-Assisted Radical Prostatectomy. **2018**, 455-462 1
- 3 Aging male and its complications - erectile dysfunction and testosterone deficiency syndrome. *Medicīa Pro Praxi*, **2018**, 15, 103-106 0
- 2 Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75
- 1 Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.. *Translational Andrology and Urology*, **2022**, 11, 124-138 2.3 1